289 related articles for article (PubMed ID: 29532104)
1. Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin αvβ6 inhibitor, in healthy participants.
Maden CH; Fairman D; Chalker M; Costa MJ; Fahy WA; Garman N; Lukey PT; Mant T; Parry S; Simpson JK; Slack RJ; Kendrick S; Marshall RP
Eur J Clin Pharmacol; 2018 Jun; 74(6):701-709. PubMed ID: 29532104
[TBL] [Abstract][Full Text] [Related]
2. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor.
Maher TM; Simpson JK; Porter JC; Wilson FJ; Chan R; Eames R; Cui Y; Siederer S; Parry S; Kenny J; Slack RJ; Sahota J; Paul L; Saunders P; Molyneaux PL; Lukey PT; Rizzo G; Searle GE; Marshall RP; Saleem A; Kang'ombe AR; Fairman D; Fahy WA; Vahdati-Bolouri M
Respir Res; 2020 Mar; 21(1):75. PubMed ID: 32216814
[TBL] [Abstract][Full Text] [Related]
3. Translational pharmacology of an inhaled small molecule αvβ6 integrin inhibitor for idiopathic pulmonary fibrosis.
John AE; Graves RH; Pun KT; Vitulli G; Forty EJ; Mercer PF; Morrell JL; Barrett JW; Rogers RF; Hafeji M; Bibby LI; Gower E; Morrison VS; Man Y; Roper JA; Luckett JC; Borthwick LA; Barksby BS; Burgoyne RA; Barnes R; Le J; Flint DJ; Pyne S; Habgood A; Organ LA; Joseph C; Edwards-Pritchard RC; Maher TM; Fisher AJ; Gudmann NS; Leeming DJ; Chambers RC; Lukey PT; Marshall RP; Macdonald SJF; Jenkins RG; Slack RJ
Nat Commun; 2020 Sep; 11(1):4659. PubMed ID: 32938936
[TBL] [Abstract][Full Text] [Related]
4. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial.
Birring SS; Wijsenbeek MS; Agrawal S; van den Berg JWK; Stone H; Maher TM; Tutuncu A; Morice AH
Lancet Respir Med; 2017 Oct; 5(10):806-815. PubMed ID: 28923239
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of Nemiralisib Administered via the Ellipta Dry Powder Inhaler to Healthy Subjects.
Wilson R; Jarvis E; Montembault M; Hamblin JN; Hessel EM; Cahn A
Clin Ther; 2018 Aug; 40(8):1410-1417. PubMed ID: 30055824
[TBL] [Abstract][Full Text] [Related]
6. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability, and pharmacokinetics of a single ascending dose of baicalein chewable tablets in healthy subjects.
Li M; Shi A; Pang H; Xue W; Li Y; Cao G; Yan B; Dong F; Li K; Xiao W; He G; Du G; Hu X
J Ethnopharmacol; 2014 Oct; 156():210-5. PubMed ID: 25219601
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis.
Khoo JK; Montgomery AB; Otto KL; Surber M; Faggian J; Lickliter JD; Glaspole I
J Aerosol Med Pulm Drug Deliv; 2020 Feb; 33(1):15-20. PubMed ID: 30698487
[No Abstract] [Full Text] [Related]
9. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses.
Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE
Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776
[TBL] [Abstract][Full Text] [Related]
10. First-in-man study of ACT-709478, a novel selective triple T-type calcium channel blocker.
Richard M; Kaufmann P; Kornberger R; Dingemanse J
Epilepsia; 2019 May; 60(5):968-978. PubMed ID: 31004346
[TBL] [Abstract][Full Text] [Related]
11. MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers.
Boot JD; De Haas SL; Van Gerven JM; De Smet M; Leathem T; Wagner J; Denker A; Miller D; Van Doorn MB; Schoemaker RC; Cohen AF; Diamant Z
Pulm Pharmacol Ther; 2008; 21(3):573-7. PubMed ID: 18321743
[TBL] [Abstract][Full Text] [Related]
12. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects.
Shen Z; Gillen M; Miner JN; Bucci G; Wilson DM; Hall JW
Drug Des Devel Ther; 2017; 11():2077-2086. PubMed ID: 28744099
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
Vaughan D; Speed J; Medve R; Andrews JS
Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.
Mariotti F; Govoni M; Lucci G; Santoro D; Nandeuil MA
Int J Chron Obstruct Pulmon Dis; 2018; 13():3399-3410. PubMed ID: 30425469
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective Autotaxin inhibitor, in healthy subjects: A phase I randomized placebo-controlled trial.
Yang L; Shu P; Wu N; Hu M; Luo Z
Eur J Pharm Sci; 2023 Oct; 189():106552. PubMed ID: 37532064
[TBL] [Abstract][Full Text] [Related]
17. Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator.
Skrumsager BK; Kiehr B; Pedersen PC; Gerrits M; Watson N; Bjarnason K
Br J Clin Pharmacol; 2002 Mar; 53(3):284-95. PubMed ID: 11874392
[TBL] [Abstract][Full Text] [Related]
18. Safety, tolerability, and pharmacokinetics of sumatriptan suppositories following single and multiple doses in healthy volunteers.
Kunka RL; Hussey EK; Shaw S; Warner P; Aubert B; Richard I; Fowler PA; Pakes GE
Cephalalgia; 1997 Jun; 17(4):532-40. PubMed ID: 9209775
[TBL] [Abstract][Full Text] [Related]
19. Safety, Tolerability, and Pharmacokinetic Profile of the Novel Translocator Protein 18 kDa Antagonist ONO-2952 in Healthy Volunteers.
Suto F; Wood AT; Kobayashi M; Komaba J; Duffy K; Bruce M
Clin Ther; 2015 Sep; 37(9):2071-84. PubMed ID: 26249232
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability and pharmacokinetics of BIBN 4096 BS, the first selective small molecule calcitonin gene-related peptide receptor antagonist, following single intravenous administration in healthy volunteers.
Iovino M; Feifel U; Yong CL; Wolters JM; Wallenstein G
Cephalalgia; 2004 Aug; 24(8):645-56. PubMed ID: 15265053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
